Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 8 | 10 |
| 1.1 List of Tables | 13 | 3 |
| 1.2 List of Figures | 16 | 2 |
| 2 Introduction | 18 | 2 |
| 2.1 Catalyst | 18 | 1 |
| 2.2 Related Reports | 19 | 1 |
| 3 Industry Overview | 20 | 10 |
| 3.1 Infectious Disease POCT Overview | 20 | 1 |
| 3.2 Reimbursement Trends | 21 | 1 |
| 3.2.1 US | 21 | 2 |
| 3.2.2 France | 23 | 1 |
| 3.2.3 Germany | 23 | 1 |
| 3.2.4 Italy | 23 | 1 |
| 3.2.5 Spain | 24 | 1 |
| 3.2.6 UK | 24 | 1 |
| 3.2.7 Japan | 24 | 1 |
| 3.2.8 China | 25 | 1 |
| 3.2.9 India | 25 | 1 |
| 3.2.10 Brazil | 25 | 2 |
| 3.3 Mergers, Acquisitions, and Key Partnerships | 27 | 3 |
| 4 Unmet Needs | 30 | 5 |
| 4.1 Multiplexing | 30 | 1 |
| 4.2 Sensitivity of Infectious Disease Immunoassays | 30 | 1 |
| 4.3 Analytical Performance | 31 | 1 |
| 4.4 Data Recording and Management | 32 | 1 |
| 4.5 Infectious Disease POCT to Curb Usage of Antibiotics | 33 | 1 |
| 4.6 Cost-Effectiveness Data | 33 | 1 |
| 4.7 Primary Care Physician Needs | 34 | 1 |
| 5 Competitive Assessment | 35 | 39 |
| 5.1 Company Share Analysis | 35 | 1 |
| 5.1.1 Global | 35 | 1 |
| 5.2 Alere | 36 | 1 |
| 5.2.1 Overview | 36 | 1 |
| 5.2.2 Marketed Products Assessment | 37 | 3 |
| 5.2.3 SWOT Analysis | 40 | 1 |
| 5.3 Beckman Coulter | 40 | 1 |
| 5.3.1 Overview | 40 | 1 |
| 5.3.2 Marketed Products Assessment | 41 | 1 |
| 5.3.3 SWOT Analysis | 42 | 1 |
| 5.4 BioMerieux | 42 | 1 |
| 5.4.1 Overview | 42 | 2 |
| 5.4.2 Marketed Products Assessment | 44 | 1 |
| 5.4.3 SWOT Analysis | 45 | 1 |
| 5.5 Cepheid | 45 | 1 |
| 5.5.1 Overview | 45 | 1 |
| 5.5.2 Marketed Products Assessment | 46 | 2 |
| 5.5.3 SWOT Analysis | 48 | 1 |
| 5.6 Chembio Diagnostics | 49 | 1 |
| 5.6.1 Overview | 49 | 1 |
| 5.6.2 Marketed Products Assessment | 50 | 1 |
| 5.6.3 SWOT Analysis | 51 | 1 |
| 5.7 Meridian Bioscience | 51 | 1 |
| 5.7.1 Overview | 51 | 2 |
| 5.7.2 Marketed Products Assessment | 53 | 1 |
| 5.7.3 SWOT Analysis | 54 | 1 |
| 5.8 OraSure Technologies | 55 | 1 |
| 5.8.1 Overview | 55 | 1 |
| 5.8.2 Marketed Products Assessment | 56 | 1 |
| 5.8.3 SWOT Analysis | 57 | 1 |
| 5.9 Quidel | 57 | 1 |
| 5.9.1 Overview | 57 | 2 |
| 5.9.2 Marketed Products Assessment | 59 | 1 |
| 5.9.3 SWOT Analysis | 60 | 1 |
| 5.10 Roche Diagnostics | 61 | 1 |
| 5.10.1 Overview | 61 | 1 |
| 5.10.2 Marketed Products Assessment | 62 | 1 |
| 5.10.3 SWOT Analysis | 62 | 1 |
| 5.11 Trinity Biotech | 63 | 1 |
| 5.11.1 Overview | 63 | 1 |
| 5.11.2 Marketed Products Assessment | 64 | 1 |
| 5.11.3 SWOT Analysis | 65 | 1 |
| 5.12 Other Companies | 66 | 1 |
| 5.12.1 North American Market Companies | 66 | 5 |
| 5.12.2 European Market Companies | 71 | 2 |
| 5.12.3 APAC and Other Markets Companies | 73 | 1 |
| 6 Pipeline Assessment | 74 | 9 |
| 6.1 Overview | 74 | 1 |
| 6.2 Early Development Pipeline | 75 | 3 |
| 6.3 Pre-clinical Stage Pipeline | 78 | 1 |
| 6.4 Clinical Stage Pipeline | 79 | 3 |
| 6.5 Products in the Approval Process | 82 | 1 |
| 7 Market Outlook | 83 | 59 |
| 7.1 Test Trends | 83 | 1 |
| 7.1.1 HIV POCT | 83 | 1 |
| 7.1.2 Influenza POCT | 84 | 2 |
| 7.1.3 HBV POCT | 86 | 2 |
| 7.1.4 HCV POCT | 88 | 1 |
| 7.1.5 C. difficile POCT | 89 | 1 |
| 7.2 Market Dynamics | 90 | 1 |
| 7.2.1 Driver: Fast Turnaround Time | 90 | 1 |
| 7.2.2 Driver: Emergence of Molecular Infectious Disease POCT | 90 | 1 |
| 7.2.3 Driver: Expansion POCT Menu | 91 | 1 |
| 7.2.4 Driver: CLIA-Waived Status for POCT | 92 | 1 |
| 7.2.5 Driver: Rising Prevalence of Diseases | 92 | 1 |
| 7.2.6 Barriers: Management of POCT | 92 | 2 |
| 7.2.7 Barriers: Competition with Laboratory Tests | 94 | 1 |
| 7.2.8 Barriers: Reimbursement | 95 | 1 |
| 7.2.9 Barriers: Regulatory Compliance | 96 | 1 |
| 7.3 Market Outlook By Market Segment | 96 | 1 |
| 7.3.1 Global Overview | 96 | 3 |
| 7.3.2 HIV POCT | 99 | 2 |
| 7.3.3 Influenza POCT | 101 | 2 |
| 7.3.4 HBV POCT | 103 | 1 |
| 7.3.5 HCV POCT | 104 | 1 |
| 7.3.6 C. difficile POCT | 105 | 1 |
| 7.3.7 Molecular POCT Analyzers | 106 | 1 |
| 7.4 Market Outlook By Geography | 107 | 1 |
| 7.4.1 Global Overview | 107 | 4 |
| 7.4.2 US | 111 | 3 |
| 7.4.3 France | 114 | 3 |
| 7.4.4 Germany | 117 | 3 |
| 7.4.5 Italy | 120 | 3 |
| 7.4.6 Spain | 123 | 3 |
| 7.4.7 UK | 126 | 3 |
| 7.4.8 Japan | 129 | 3 |
| 7.4.9 China | 132 | 4 |
| 7.4.10 India | 136 | 3 |
| 7.4.11 Brazil | 139 | 3 |
| 8 Appendix | 142 | 17 |
| 8.1 Bibliography | 142 | 4 |
| 8.2 Abbreviations | 146 | 5 |
| 8.3 Report Methodology | 151 | 4 |
| 8.3.1 Overview | 151 | 1 |
| 8.3.2 Coverage | 151 | 1 |
| 8.3.3 Secondary Research | 151 | 1 |
| 8.3.4 Forecasting Methodology | 152 | 1 |
| 8.3.5 Primary Research Key Opinion Leader Interviews | 153 | 1 |
| 8.3.6 Primary Research Physician and Industry Interviews | 154 | 1 |
| 8.3.7 Expert Panel Validation | 154 | 1 |
| 8.4 About the Team | 155 | 2 |
| 8.4.1 Analysts | 155 | 1 |
| 8.4.1.1 Wenlu Hu, Bsc, Medical Devices Analyst (Author) | 155 | 1 |
| 8.4.1.2 Andrew Thompson, Ph.D., Managing Analyst and Product Manager | 155 | 1 |
| 8.4.1.3 Linda Tian, MSc, Managing Analyst, Medical Devices | 156 | 1 |
| 8.4.2 Tyler Fletcher, Global Head of Medical Devices | 156 | 1 |
| 8.5 About MediPoint | 157 | 1 |
| 8.6 About GlobalData | 157 | 1 |
| 8.7 Disclaimer | 157 | 2 |